All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

What are the critical issues to address for outpatient administration of CAR T-cell therapy?

During the 3rd European CAR T-cell Meeting, the Lymphoma Hub spoke to Ulrich Jäger, Medical University of Vienna, Vienna, AT. We asked, What are the critical issues that need to be addressed to achieve outpatient administration of CAR T-cell therapy?

What are the critical issues to address for outpatient administration of CAR T-cell therapy?

Ulrich Jäger discusses this question with reference to the OUTREACH trial and the importance of patient selection.

Share: